^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EPIM-001

i
Other names: EPIM-001, EPIM 001, EPIM001
Company:
Elpis Biopharma
Drug class:
PD-L1 inhibitor, CD122 agonist
Related drugs:
over2years
Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities (AACR 2022)
Furthermore, in the human breast cancer cell line MDA-MB-231, EPIM-001 showed stronger tumor growth inhibition compared to Keytruda. EPIM-001 is a promising immune modulating drug candidate that selectively activates CD8+ T cells and NK Cells with strong anti-tumor activity and safe profile for both immune checkpoint sensitive and insensitive PD-L1 positive tumors.
Late-breaking abstract
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • EPIM-001